Isampulu yoKhupho lweSampulu
Igama lemveliso
I-Reagent yoKhupho lweSampuli yeMacro kunye neMicro-Test
Isatifikethi
I-CE, i-FDA, i-NMPA
Izinto eziphambili
| Igama | Izinto eziphambili | Icandeloiinkcukacha | Ubungakanani |
| Ukukhutshwa kweSampulii-reagent | I-Dithiothreitol, i-sodium dodecyli-sulfate (SDS), i-RNase inhibitor,i-surfactant, amanzi acocekileyo | 0.5mL/Ibhotile | Ibhotile engama-50 |
Qaphela: Izinto ezikwiibhetshi ezahlukeneyo zeekiti azinakutshintshwa.
Iimeko zokugcina kunye nexesha elihlala lihleli
Gcina kwaye uthuthe kubushushu begumbi. Ixesha lokugcinwa kweshelufu ziinyanga ezingama-24.
Izixhobo ezisebenzayo
Izixhobo kunye nezixhobo ngexesha lokucubungula isampuli, ezinje ngeepipettes, ii-vortex mixers,iibhafu zamanzi, njl.
Iimfuno zesampulu
Iiswabhu ze-oropharyngeal eziqokelelweyo ezisandula ukuqokelelwa, iiswabhu ze-nasopharyngeal.
Uchaneko
Xa le khithi isetyenziselwa ukutsalwa kwi-CV yesalathiso sokuchaneka kwangaphakathi kwiikopi ezili-10, i-coefficient of variation (CV, %) yexabiso le-Ct ayidluli kwi-10%.
Umahluko phakathi kweqela
Xa ireferensi yokuchaneka kwangaphakathi ivavanywa kwiibhetshi ezintathu zeekhithi eziphantsi kwemveliso yovavanyo xa kutsalwa ngokuphindaphindiweyo kwaye, i-coefficient of variation (CV, %) yexabiso le-Ct ayidluli kwi-10%.
Uthelekiso lwentsebenzo
● Ukuthelekiswa kokusebenza kakuhle kokukhupha
| Ukuthelekiswa kokusebenza kakuhle kwendlela yeentsimbi zemagnethi kunye nesikhupheli sesampuli | ||||
| ukugxila | indlela yeentsimbi zemagnethi | isampula yokukhulula | ||
| i-orfab | N | i-orfab | N | |
| 20000 | 28.01 | 28.76 | 28.6 | 29.15 |
| 2000 | 31.53 | 31.9 | 32.35 | 32.37 |
| 500 | 33.8 | 34 | 35.25 | 35.9 |
| 200 | 35.25 | 35.9 | 35.83 | 35.96 |
| 100 | 36.99 | 37.7 | 38.13 | susa |
Ukusebenza kakuhle kokukhupha isampuli ye-sample releaser kwakufana nendlela yokusebenzisa ii-magnetic beads, kwaye uxinzelelo lwe-pathogen lunokuba yi-200Copies/mL.
● Uthelekiso lwexabiso le-CV
| Ukuphinda-phinda kokukhutshwa kwesampuli yokukhulula | ||
| uxinzelelo:5000Iikopi/mL | I-ORF1ab | N |
| 30.17 | 30.38 | |
| 30.09 | 30.36 | |
| 30.36 | 30.26 | |
| 30.03 | 30.48 | |
| 30.14 | 30.45 | |
| 30.31 | 30.16 | |
| 30.38 | 30.7 | |
| 30.72 | 30.79 | |
| CV | 0.73% | 0.69% |
Xa kuvavanywa iikopi ezingama-5,000 /mL, i-CV ye-orFab kunye ne-N yayiyi-0.73% kunye ne-0.69%, ngokulandelelana.
